Dr. Aaron L. Boster, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Cincinnati College of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 98
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Cincinnati College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
OH license 35091626
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Marion General Hospital Marion, OH
Medical groups
- Levey Innovative Therapeutics LLC (3 clinicians)
- The Boster Center for Multiple Sclerosis, LLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 98
- Services billed
- 34,110
- Patients’ average age
- 61
| Service | Times | Patients |
|---|---|---|
| Injection, ocrelizumab, 1 mg | 22,203 | 24 |
| Injection, dexamethasone sodium phosphate, 1 mg | 271 | 14 |
| Established patient office or other outpatient visit, 30-39 minutes | 166 | 61 |
| Injection of additional new drug or substance into vein | 79 | 24 |
| Administration of chemotherapy into vein, 1 hour or less | 78 | 28 |
| Established patient office or other outpatient visit, 40-54 minutes | 74 | 44 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 66 | 23 |
| Administration of chemotherapy into vein, each additional hour | 56 | 24 |
| Injection, diphenhydramine hcl, up to 50 mg | 41 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Baclofen Other prescribers in Columbus, OH | 269 |
| Gabapentin Other prescribers in Columbus, OH | 160 |
| Dalfampridine Er (dalfampridine) | 142 |
| Bupropion Xl (bupropion hcl) Other prescribers in Columbus, OH | 116 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Columbus, OH | 111 |
| Duloxetine Hcl Other prescribers in Columbus, OH | 94 |
| Modafinil Other prescribers in Columbus, OH | 70 |
| Sertraline Hcl Other prescribers in Columbus, OH | 68 |
| Tizanidine Hcl Other prescribers in Columbus, OH | 65 |
| Myrbetriq (mirabegron) Other prescribers in Columbus, OH | 38 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 67 payments worth $64,166 in total to this clinician.
| Ares Trading SA | $25,789 |
|---|---|
| EMD Serono, Inc. | $23,435 |
| Genentech USA, Inc. | $7,404 |
| Genzyme Corporation | $4,309 |
| Amgen Inc. | $2,815 |
| Novartis Pharmaceuticals Corporation | $195 |
| AbbVie Inc. | $84.80 |
| Mallinckrodt Hospital Products Inc. | $82.49 |
| Compensation for services other than consulting (speaking, faculty) | $39,976 |
|---|---|
| Travel and Lodging | $13,097 |
| Consulting Fee | $9,045 |
| Food and Beverage | $2,048 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ares Trading SA Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $12,810 |
| Ares Trading SA Nov 6, 2025 | Travel and Lodging travel to Vienna, Austria Company’s descriptionSpeaking Services (Transportation) | $11,925 |
| Genentech USA, Inc. Nov 15, 2025 | Consulting Fee Ocrevus · Immunology | $6,525 |
| EMD Serono, Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $6,263 |
| Genzyme Corporation May 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,955 |
| EMD Serono, Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaker Training (Fee For Service) | $3,340 |
| Amgen Inc. Dec 10, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $2,750 |
| EMD Serono, Inc. Oct 2, 2025 | Consulting Fee Mavenclad · Neurology Company’s descriptionConsulting Services (Fee For Service) | $2,520 |
| EMD Serono, Inc. Jul 14, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $2,088 |
| EMD Serono, Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $2,088 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Dec 10, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $2,750 |
| Ares Trading SA Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $12,810 |
| Ares Trading SA Dec 4, 2025 | Travel and Lodging travel to Vienna, Austria Company’s descriptionSpeaking Services (Transportation) | $155 |
| Genentech USA, Inc. Nov 15, 2025 | Consulting Fee Ocrevus · Immunology | $6,525 |
| Genentech USA, Inc. Nov 15, 2025 | Travel and Lodging Ocrevus · Immunology · travel to Nashville, TN · in-kind | $340 |
| Genentech USA, Inc. Nov 15, 2025 | Travel and Lodging Ocrevus · Immunology · travel to Nashville, TN | $102 |
| EMD Serono, Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $2,088 |
| Ares Trading SA Nov 6, 2025 | Travel and Lodging travel to Vienna, Austria Company’s descriptionSpeaking Services (Transportation) | $11,925 |
| Ares Trading SA Nov 6, 2025 | Travel and Lodging travel to Vienna, Austria Company’s descriptionSpeaking Services (Lodging) | $576 |
| EMD Serono, Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $2,088 |
| EMD Serono, Inc. Oct 2, 2025 | Consulting Fee Mavenclad · Neurology Company’s descriptionConsulting Services (Fee For Service) | $2,520 |
| EMD Serono, Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $6,263 |
| EMD Serono, Inc. Jul 14, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $2,088 |
| Genzyme Corporation May 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,955 |
| EMD Serono, Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaker Training (Fee For Service) | $3,340 |
| EMD Serono, Inc. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $2,088 |
| EMD Serono, Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $2,088 |
| EMD Serono, Inc. Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaker Training (Fee For Service) | $418 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 5 companies. The companies reported $802,667 in research payments for these studies, mostly to the institutions running them.
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473 - A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Genzyme Corporation · Active, not recruiting · NCT06372145 - A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Scle…
Amgen Inc. - Evaluation of Fenebrutinib in RMS patients
Genentech, Inc. - A Randomized, Double Blind, Parallel Group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692, and Ocrevus (Ocrelizumab) in Subjects with Relapsing Remitting Multiple Scl…
Amgen Inc. - Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Genzyme Corporation · Completed · NCT04458051 - Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - Study of ocrelizumab in PPMS patients assessing upper limb function
Hoffmann-la Roche Limited - A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
Novartis Pharmaceuticals Corporation - Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Genzyme Corporation · Completed · NCT04411641
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.